Related Experiment Video

Updated: Jul 13, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Molecular therapy in urologic oncology

Michael Froehner1, Oliver W Hakenberg, Manfred P Wirth

  • 1Department of Urology, University Hospital, Technical University of Dresden, Dresden, Germany. Michael.Froehner@uniklinikum-dresden.de

Urologia Internationalis
|July 14, 2007
PubMed

Insights

Molecular therapies show promise in advanced renal cell carcinoma, stabilizing disease and improving survival. Research is ongoing for other urologic cancers like prostate, bladder, and testicular cancers.

Area of Science:

  • Urologic Oncology
  • Molecular Therapy
  • Cancer Research

Background:

  • Advanced renal cell carcinoma (RCC) has been largely treatment-refractory.
  • The von Hippel-Lindau (VHL) metabolic pathway is implicated in RCC carcinogenesis and progression.
  • Significant advances in molecular therapy have emerged for urologic oncology.

Purpose of the Study:

  • To review recent advances in molecular therapy for urologic malignancies.
  • To discuss the efficacy of targeted agents in advanced renal cell carcinoma.
  • To explore the potential of molecular therapies in prostate, bladder, and testicular cancers.

Main Methods:

  • Review of recent clinical studies and drug development in urologic oncology.
  • Focus on agents targeting the VHL pathway in renal cell carcinoma.
  • Analysis of preliminary data for molecular therapies in other urologic cancers.

Main Results:

  • Multikinase inhibitors (sorafenib, sunitinib) and mTOR inhibitors (temsirolimus) stabilize advanced RCC and improve survival.
  • Limited data exist for molecular therapies in prostate, bladder, and testicular cancers.
  • High-dose calcitriol and thalidomide show potential in hormone-refractory prostate cancer.

Conclusions:

  • Molecular therapies, particularly targeting the VHL pathway, offer new treatment options for advanced renal cell carcinoma.
  • Further research is warranted to explore the potential of targeted therapies and drug combinations in other urologic malignancies.
  • Despite current limitations, the field holds significant promise for improving outcomes in urologic oncology.

More Related Videos

Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode04:45

Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...